PROMISE: CE/BZA in postmenopausal, ER+ ductal carcinoma in situ

23 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the Phase II PROMISE study (NCT02694809), which assesses the presurgical use of conjugated estrogen/bazedoxifene (CE/BZA) versus placebo in postmenopausal women with ER-positive ductal carcinoma in situ (DCIS). CE/BZA significantly reduced Ki-67 expression in ductal epithelium without adversely affecting quality-of-life measures. These results support CE/BZA as a safe intervention for managing menopausal symptoms and suggest potential for reducing the risk of invasive breast cancer development. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo